International Consensus Guideline for Anticancer Drug Dosing in Kidney Dysfunction

May 2021
Rationale for guideline development

- Inconsistencies in assessing and defining kidney function for drug dosing in cancer
- Large variability in recommended dose adjustments in international guidelines and published studies
- Limited evidence for dose adjustment in older anticancer drugs
- Previous attempt by eviQ to standardise dose adjustments for organ dysfunction
Expert multi-disciplinary, multi-national working party

Guideline methodology based on international standards

Literature search

GRADE approach with evidence assessment and recommendation development

Small working party panel discussions

Working party consensus

External stakeholder consultation and endorsement
Use eGFR via CKD-EPI to guide the assessment of kidney function, except when directly measured GFR is clinically necessary.

For anticancer drugs where the dose is dependent on kidney function, eGFR determined using CKD-EPI is suggested to guide dosing in the absence of a measured GFR.

KDIGO CKD categories are suggested to guide stepwise dose reductions of anticancer drugs in kidney dysfunction.